ImmunoGenesis is a startup based in the United States, most recent round Series B, 1 tracked investor.
Based in the United States, ImmunoGenesis is a startup founded in 2020. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
ImmunoGenesis is a clinical-stage biopharmaceutical company focused on developing immunotherapies for the treatment of cancer, specifically targeting cold tumors resistant to existing treatments. The company’s lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor designed to overcome immune resistance mechanisms in tumors.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.